Company profile: Ring Therapeutics
1.1 - Company Overview
Company description
- Provider of programmable genetic medicines enabled by AnelloScope (anellovirus discovery), AnelloScreen (tissue tropism, redosability, potency, immunogenicity), AnelloDesign (computational vector design), AnelloVector (non-integrating engineered viral nucleic acid delivery), AnelloLP (surface-payload viral particles for immune evasion), and AnelloBricks (scalable manufacturing for clinical and commercial production).
Products and services
- AnelloVector: Custom-engineered viral particles that deliver nucleic acids to cells across diverse tissue types without integrating into chromosomal DNA, enabling gene transfer while avoiding genomic insertion
- AnelloDesign: Bioinformatics-driven pipeline that integrates genomic information to architect AnelloVectors with precise tissue targeting and reduced immunogenicity
- AnelloBricks: Industrial-scale manufacturing platform that produces therapies efficiently at scale, supporting clinical development and commercial production of AnelloVector drug products
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Ring Therapeutics
Sequenta
HQ: United States
Website
- Description: Provider of clinical diagnostics and immune profiling tools based on a platform for understanding immune system status. Products include clonoSEQ for MRD detection and monitoring in multiple myeloma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia; immunoSEQ for sequencing T- and B-cell receptors; T-Detect to identify recent or past infections, including COVID-19; and an Immune Medicine Platform mapping immune receptors to antigens.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sequenta company profile →
Bluebird Bio
HQ: United States
Website
- Description: Provider of gene therapies for severe genetic and rare diseases, developing gene addition treatments that modify patient cells to address underlying genetic causes using lentiviral vectors. Products include LentiGlobin for sickle cell disease, Lenti-D for cerebral adrenoleukodystrophy, and Zynteglo for beta-thalassemia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bluebird Bio company profile →
Caribou Biosciences
HQ: United States
Website
- Description: Provider of CRISPR genome-editing technologies and allogeneic CAR-T cell therapies for oncology. Offers chRDNA to enhance precision and reduce off-target effects; off-the-shelf CAR-T therapies for hematologic malignancies and autoimmune diseases; and candidates CB-010 (anti-CD19 for B cell non-Hodgkin lymphoma), CB-011 (anti-BCMA for multiple myeloma), and CB-012 (anti-CLL-1 for acute myeloid leukemia).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Caribou Biosciences company profile →
Devyser
HQ: Sweden
Website
- Description: Provider of diagnostic kits for complex DNA testing in oncology, hereditary diseases, and transplantation, used to guide targeted cancer therapies and enable genetic testing. Sold in 60+ countries, offerings include NGS-based tests for thalassemia, cystic fibrosis, familial hypercholesterolemia, thrombophilia, HFE mutations, and Y-chromosome microdeletions linked to male infertility.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Devyser company profile →
Nextcode
HQ: United States
Website
- Description: Provider of sequence-based clinical diagnostics and genome interpretation solutions that address big data challenges, leveraging technology developed over more than 16 years at deCODE genetics to enable the widespread incorporation of genome sequence data into patient diagnosis and care.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nextcode company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Ring Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Ring Therapeutics
2.2 - Growth funds investing in similar companies to Ring Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Ring Therapeutics
4.2 - Public trading comparable groups for Ring Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →